Anteris Technologies Global CORP 8-K filings

Anteris Technologies reported its Q1 2025 financial results, highlighted by the IDE submission for the PARADIGM Trial and the treatment of over 100 patients with DurAVR THV.

Anteris Technologies announces a clinical milestone of treating over 100 patients worldwide with its DurAVR Transcatheter Heart Valve (THV).

Anteris Technologies announces favorable one-year patient outcomes for its DurAVR Transcatheter Heart Valve (THV), demonstrating sustained hemodynamic performance and zero prosthesis-patient mismatch (PPM) in small annuli patients.

Anteris Technologies reports its full year 2024 financial results, highlighting a successful IPO, progress on the DurAVR THV Pivotal Trial, and a strong cash position.

Anteris Technologies Global Corp. has appointed David St Denis as President and a Class II director, effective immediately, while he continues to serve as Chief Operating Officer.

Anteris Technologies reports the partial exercise of the over-allotment option related to its IPO and the conclusion of the stabilisation period.

Anteris Technologies Global Corp. will redeem all outstanding convertible notes for approximately $5.9 million following its recent IPO and corporate restructuring.

Anteris Technologies Global Corp. successfully completed its IPO and a series of reorganization transactions, including acquiring Anteris Technologies Ltd.